<table border="0" cellpadding="0" cellspacing="0" width="533" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<tbody>
<tr stylecode="Botrule">
<td align="center" stylecode="Lrule Rrule" valign="top">
<content stylecode="bold">Concomitant</content>
<content stylecode="bold"></content>
<content stylecode="bold">Drug Name or</content>
<content stylecode="bold"></content>
<content stylecode="bold">Drug </content>
<content stylecode="bold">Class</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">
<content stylecode="bold">Clinical Rationale</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">
<content stylecode="bold">Clinical</content>
<content stylecode="bold"> Recommendation</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td align="left" stylecode="Lrule Rrule" valign="top">
<br/>StrongCYP3A4Inhibitors (e.g.,itraconazole,clarithromycin) or strongCYP2D6inhibitors (e.g.,quinidine,fluoxetine,paroxetine)Â <br/>
</td>
<td stylecode="Rrule" valign="top">The concomitant use of aripiprazole tablets withstrong CYP3A4 orCYP2D6inhibitorsincreasedthe exposure ofaripiprazole tabletscomparedto the use of aripiprazole tabletsalone<content stylecode="italics">[seeCLINICALPHARMACOLOGY(<linkhtml href="#Section_12.3">12.3</linkhtml>)].</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Withconcomitant use of aripiprazole tablets with a strongCYP3A4inhibitororCYP2D6inhibitor, reducethearipiprazole tablets dosage<content stylecode="italics">[see DOSAGEANDADMINISTRATION(<linkhtml href="#Section_2.3">2.7</linkhtml>)].</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">StrongCYP3A4Inducers (e.g.,carbamazepine,rifampin)<br/>
</td>
<td stylecode="Rrule" valign="top">The concomitant use of aripiprazole tabletsandcarbamazepine decreased the exposure of aripiprazole tablets compared to the use of aripiprazole tablets alone <content stylecode="italics">[see</content>
<content stylecode="italics">CLINICALPHARMACOLOGY(<linkhtml href="#Section_12.3">12.3</linkhtml>)].</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Withconcomitant use of aripiprazole tablets with a strongCYP3A4inducer, consider increasing the aripiprazole tabletsdosage<content stylecode="italics">[see DOSAGE ANDADMINISTRATIO(<linkhtml href="#Section_2.3">2.7</linkhtml>)].</content>
<br/>
</td>
</tr>
<tr stylecode="Botrule">
<td stylecode="Lrule Rrule" valign="top">AntihypertensiveDrugs<br/>
</td>
<td stylecode="Rrule" valign="top">Duetoitsalphaadrenergicantagonism,aripiprazole tablets hasthepotentialtoenhance the effect of certainantihypertensive agents.<br/>
</td>
<td stylecode="Rrule" valign="top">Monitor bloodpressureand adjustdoseaccordingly<content stylecode="italics">[seeWARNINGS AND PRECAUTIONS(<linkhtml href="#Section_5.7">5.7</linkhtml>)].</content>
<br/>
</td>
</tr>
<tr>
<td stylecode="Lrule Rrule" valign="top">Benzodiazepines(e.g., lorazepam)<br/>
</td>
<td stylecode="Rrule" valign="top">Theintensityofsedationwas greaterwith the combination of oral aripiprazole tabletsandlorazepam as comparedtothat observedwith aripiprazole alone.Theorthostatichypotension observed wasgreaterwith the combination as comparedtothatobserved withlorazepamalone<content stylecode="italics">[seeWARNINGSANDPRECAUTIONS(<linkhtml href="#Section_5.7">5.7</linkhtml>)]</content>
<br/>
</td>
<td stylecode="Rrule" valign="top">Monitorsedation and blood pressure.Adjust dose accordingly.<br/>
</td>
</tr>
</tbody>
</table>